Physician profile
David Bejar
NPI 1659714921
$4,676.79
in general payments reported to CMS, 2019-2025
25 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $400 · 2021: $684 · 2022: $1,065 · 2023: $752 · 2024: $1,027 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,268.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $713.03 | 2019-2024 | Xarelto |
| Amgen INC. | $662.32 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $556.76 | 2019-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $430.59 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $322.63 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $296.18 | 2020-2025 | Farxiga, Wainua |
| Abbott Laboratories | $267.60 | 2021-2024 | Navitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $240.75 | 2020-2023 | Lifevest |
| Pfizer INC. | $195.64 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $149.94 | 2024 | Arcalyst |
| Philips North America LLC | $130.26 | 2022 | |
| Medtronic, INC. | $118.97 | 2022-2025 | Venaseal |
| Boston Scientific Corporation | $118.16 | 2022-2025 | Watchman Flx, Varithena Administration Pack |
| Atricure, INC. | $103.17 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.10 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $40.61 | 2024-2025 | Assure Wcd |
| Inspire Medical Systems, INC. | $40.00 | 2024 | Inspire |
| Lexicon Pharmaceuticals, INC. | $35.97 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $35.93 | 2019 | |
| Ucb, INC. | $25.71 | 2024 | Rystiggo |
| Scpharmaceuticals INC. | $25.55 | 2024 | |
| Impulse Dynamics (USA) INC. | $23.74 | 2022 | |
| Merck Sharp & Dohme LLC | $19.10 | 2023 | Verquvo |
| Chiesi USA, INC. | $18.48 | 2022 | |
| Lilly USA, LLC | $14.60 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bejar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.